Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence
Real-world data confirm Ra-223's survival benefit is closely associated with treatment completion and baseline clinical factors. The findings support risk-stratified patient selection and tailored management in mCRPC.
Authors
- Xinwei Zhu
- Baolin Song (ORCID: https://orcid.org/0000-0001-7834-8064)
- Huan Shao
- He Yanmei
- Pengfei Qin (ORCID: https://orcid.org/0000-0002-2402-3405)
Institutions
- First Hospital of Jiaxing (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fonc.2025.1672802
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52